ADMA (ADMA Biologics) Total Payout Ratio: 0.79 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADMA ADMA Biologics Inc ADMA
64 GF Score
Price $8.76
GF Value $18.13
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Total Payout Ratio?

ADMA Biologics ADMA +0.40% 64 Total Payout Ratio is 0.79 as of Jul. 21, 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.13 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

ADMA Biologics's current Total Payout Ratio is 0.79.

ADMA Biologics Total Payout Ratio Related Terms

ADMA Biologics Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for ADMA Biologics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics Total Payout Ratio Chart

ADMA Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.69 0.98 0.00 0.00 0.22

ADMA Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.87

ADMA vs ZLAB, HRMY, STOK: Total Payout Ratio Comparison

For the Biotechnology subindustry, ADMA Biologics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADMA Biologics Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Total Payout Ratio falls into.


ADMA
64GF Score
ADMA Biologics Inc ADMA
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADMA Biologics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

ADMA Biologics's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-31.94 + 0 + 0) / 146.93
=0.22

ADMA Biologics's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-130.191 + 0 + 0) / 45.328
=2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.79 mean?
ADMA Biologics (ADMA) has a Total Payout Ratio of 0.79 as of Jul. 21, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on ADMA Biologics and its competitors.
Is ADMA Biologics' Total Payout Ratio too high?
ADMA Biologics' current Total Payout Ratio is 0.79. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Total Payout Ratio compare to ZLAB and HRMY?
ADMA Biologics' Total Payout Ratio of 0.79 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current Total Payout Ratio is 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.13, compared to a current price of $8.76 — trading 51.7% below its estimated fair value. The current Total Payout Ratio is 0.79. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Total Payout Ratio is 0.79 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $8.76 is trading 51.7% below its estimated GF Value™ of $18.13. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Total Payout Ratio: 0.79
  • GF Value™: $18.13 vs. price of $8.76 (51.7% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score

Get the complete analysis for ADMA

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.76
Price
$18.13
GF Value